Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) disclosed that executive director, co-chief executive officer and global R&D president Dr. Gan Liming bought 6,800 H shares of the company on the open market using personal funds.

The latest transaction raises Dr. Gan’s total open-market purchases to 20,000 H shares as of 10 July 2026. According to the announcement, Dr. Gan expressed confidence in the Group’s long-term development prospects and indicated that, subject to regulatory compliance, further purchases remain possible.

The board advised shareholders and potential investors to exercise caution when dealing in the company’s securities.

The announcement was signed by Chairman Liang Zicai and dated 10 July 2026.